Format

Send to

Choose Destination
Drug Discov Today. 2019 Aug 2. pii: S1359-6446(19)30283-1. doi: 10.1016/j.drudis.2019.07.007. [Epub ahead of print]

The influence of ketamine on drug discovery in depression.

Author information

1
Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, USA.
2
Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, USA. Electronic address: bashkim.kadriu@nih.gov.

Abstract

Recent research demonstrating that the glutamatergic modulator ketamine has rapid, robust and sustained antidepressant effects has been a turning point in drug discovery for depression. The recent FDA approval of esketamine for adults with treatment-resistant major depressive disorder (MDD) has further underscored the relevance of this agent in spurring investigation into novel and mechanistically distinct agents for use in depression. Over the past two decades, ketamine research has ushered in a new wave of studies seeking to not only identify its mechanism of action but also to examine the antidepressant potential of novel or repurposed agents. This article reviews the approaches that have proven particularly fruitful for the field of neuropsychiatry.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center